Skip to main content
ISRG logo

ISRG · Intuitive Surgical Inc

Track ISRG — free
$437.75 -5.84 (-1.32%)
Market Cap
$151.74B
Shares
346.64M
Volume · Nov 16 1.78M Avg daily vol (3M) 2.36M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$437.75 Open$444.38 Day$436.71–446.20 52W close$332.02–592.85 Avg vol 30d2.5M Short int7.1M · 2.0% of shares · 2.6d Short vol37% Last earningsOct 20, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 21

Up next

Jan 21, 2027 Est · unconfirmed · in 9 wks

Latest documents

2026
Nov 2
Current report 8-K Events of Oct 29
Director or officer change, or executive pay, Regulation FD disclosure

Intuitive Surgical, Inc. appointed Aaron Martin as an independent director effective January 1, 2027, expanding its board from 10 to 11 members. He will receive an annual cash retainer of $70,000 and an initial restricted stock unit grant valued at $93,333.

Oct 21
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

Intuitive Surgical had 2,023 installed da Vinci 5 systems and 487 da Vinci SP systems as of September 30, 2026; IEEPA tariff refunds reduced cost of revenue by $27.8 million and $63.7 million during the three and nine months ended September 30, 2026.

Revenue $3.05B ▲ 21.7% Net income $522.8M ▼ 25.8% Diluted EPS $1.49 ▼ 23.6%
Read from the MD&A section
Oct 20
Earnings call
Q3 2026 earnings call

Intuitive Surgical Inc reported 22% revenue growth, 15% total procedure growth, and narrowed 2026 procedure-growth guidance to 14% to 15%. Pricing actions are expected to reduce DaVinci INA revenue per procedure by approximately 3% to 5% once fully implemented.

Oct 20
Current report 8-K
Financial results

Intuitive Surgical reported third quarter 2026 revenue of $3.05 billion, up 22%, and GAAP net income of $523 million, or $1.49 per diluted share. The results included a $450 million antitrust settlement charge.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$11.58B
Trailing 12 months
Net income (TTM)
$2.96B
Trailing 12 months
Revenue growth YoY
+21.7%
Year over year
Operating margin
28.4%
Trailing 12 months
P / E (TTM)
53.8
Trailing earnings · reciprocal yield 1.9%
FCF yield
2.3%
TTM · current market cap
Return on invested capital
22.6%
Trailing 12 months
Net cash
$4.04B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-2.8%
Year over year · fewer shares
Price change (1Y)
-21.6%
Trailing year
Short interest
2.0%
Latest settlement · 2.6 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +2%
above
Price vs 50-day avg +4%
above
RSI (14) 49
neutral
MACD trend Negative
52-week position 41%
mid-range
Momentum
relative strength
Strong
1-month return +1%
trailing
6-month return +5%
trailing
YTD return −23%
this year
Relative strength +6%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $419 › 200d $429 — 200d above 50d
Institutional flow Distributing
2,075 of 2,281 funds reported for Sep 30 · net -3.3M sh shares · +139 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.04% of shares out · ▼ -3.6% MoM · 2.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
2,281 holders — mid 3-yr range
Squeeze score 50
elevated · 0–100
Fundamentals
Excellent
Revenue growth +21%
Y/Y
Gross margin 66%
contracting
EPS growth +23%
Y/Y
Valuation P/E 53.1
in line
Buyback $1.8B
remaining
Balance sheet $3.4B
net cash
Quant / Vol
risk profile
High
Volatility 35%
annualized · 1-yr
Max drawdown −44%
past year
ATR 3.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Oct 20, 2026
Worldwide da Vinci procedure growth · in 2026 Maintained 14% – 15%
Apr 21, 2026 13.5% – 15.5% changed to Oct 20, 2026 14% – 15%
Previous outlook earlier release · from the Earnings Call filed Jul 16, 2026

Still-open targets the latest release did not restate under the same label.

Da Vinci procedure growth · full year 2026 13.5% – 15.5%
Non-GAAP gross profit margin · 2026 68% – 69%
Non-GAAP operating expense growth · 2026 11% – 13%
Non-cash stock compensation expense · 2026 $880M – $900M
Other income · 2026 $315M – $335M
Non-GAAP income tax rate · 2026 22% – 23%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+2% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
49 Neutral
MACD trend
Negative Bearish
52-week position
41% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $419 › 200d $429 — 200d above 50d
Institutional flow Distributing
2,075 of 2,281 funds reported for Sep 30 · net -3.3M sh shares · +139 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.04% of shares out · ▼ -3.6% MoM · 2.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
2,281 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $332 Now $438 · 41% Range high $593
vs 200-day avg +2% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
da Vinci surgical system installed base 12,094 as of September 30, 2026 —
da Vinci surgical system placements under operating lease arrangements 291 third quarter 2026 —
da Vinci surgical system placements under usage-based operating lease arrangements 160 third quarter 2026 —
Ion endoluminal system installed base 1,152 as of September 30, 2026 —
Ion endoluminal systems placed 56 third quarter 2026 —
Non-GAAP gross profit non-GAAP $6.03B Nine Months Ended September 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP GAAP gross profit $2.08B
+$36.6M Share-based compensation expense
+$0M Long-term incentive plan expense
+$8.7M Amortization of intangible assets
+$0M Acquisition-related items
= Non-GAAP gross profit $2.13B
Non-GAAP gross profit margin non-GAAP 69.2% Nine Months Ended September 30, 2026 —
Non-GAAP income from operations non-GAAP $3.56B Nine Months Ended September 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP GAAP income from operations $592.6M
+$212.6M Share-based compensation expense
+$0.3M Long-term incentive plan expense
+$9.3M Amortization of intangible assets
+$0M Facilities asset abandonment charge
+$454.9M Litigation charges
+$0M Gains on sale of businesses and assets
+$0M Acquisition-related items
= Non-GAAP income from operations $1.27B
Non-GAAP net income attributable to Intuitive Surgical, Inc. non-GAAP $2.96B Nine Months Ended September 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP GAAP net income attributable to Intuitive Surgical, Inc. $522.8M
+$212.6M Share-based compensation expense
+$0.3M Long-term incentive plan expense
+$9.3M Amortization of intangible assets
+$0M Facilities asset abandonment charge
+$454.9M Litigation charges
+$0M Gains on sale of businesses and assets
-$0.9M (Gains) losses on strategic investments
+$0M Acquisition-related items
-$144.4M Tax adjustments (2)
-$0.1M Adjustments attributable to noncontrolling interest in joint venture
= Non-GAAP net income attributable to Intuitive Surgical, Inc. $1.05B
Worldwide procedures (da Vinci and Ion combined) 15% third quarter 2026 —
% of Total da Vinci surgical system placements (under leasing) 54% Three Months Ended June 30, 2026 filing —
% of Total revenue 85% Three Months Ended June 30, 2026 filing —
da Vinci procedures performed 889,000 the three months ended June 30, 2026 filing —
da Vinci surgical system ASP $1.59M the three months ended June 30, 2026 filing —
IEEPA tariff refunds (product) $27.5M the second quarter of 2026 filing —
IEEPA tariff refunds (service) $8.4M the second quarter of 2026 filing —
Ion procedures performed 47,900 the three months ended June 30, 2026 filing —
Ion systems placed 55 the three months ended June 30, 2026 filing —
Lease Buyouts revenue $56M Three Months Ended June 30, 2026 filing —
Operating lease revenue $262M Three Months Ended June 30, 2026 filing —
OUS da Vinci procedure growth 20% Three Months Ended June 30, 2026 filing —
Product gross profit margin 67.9% Three Months Ended June 30, 2026 filing —
Service gross profit margin 67.2% Three Months Ended June 30, 2026 filing —
Total da Vinci surgical system placements under leasing arrangements 264 Three Months Ended June 30, 2026 filing —
Total Ion system placements under leasing arrangements 31 Three Months Ended June 30, 2026 filing —
Total recurring revenue $2.47B Three Months Ended June 30, 2026 filing —
U.S. da Vinci procedure growth 12% Three Months Ended June 30, 2026 filing —
Variable lease revenue $169M Three Months Ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ISRG
Intuitive Surgical Inc
this stock
$151.74B -22.7% +20.5% 53.1 2.0%
BDX
Becton Dickinson & Co
$58.96B — +8.2% 95.8 3.0%
MDLN
Medline Inc.
$51.52B -6.7% +11.5% — 2.9%
ALC
Alcon Inc
$35.38B -6.6% +10.5% — 3.8%
RMD
Resmed Inc
$33.50B -1.1% +13.4% 21.7 7.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
2,291
% held
87.3%
Reported
2,075 of 2,281
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,223
View
Short & Settlement
Short Interest Falling
Shares short
7.1M
Days to cover
2.6d
Change
-267.3K sh
View
Short Volume
Short vol %
37%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
12
Value
$5.4K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
47.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 27, 2026
View
Financials
Financials
Revenue (FY)
$10.1B
Net income (FY)
$2.9B
EPS diluted
$7.87
View
Buybacks
Authorized
$17.4B
Remaining
$1.8B
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 2, 2026
This year
19

Intuitive Surgical, Inc. appointed Aaron Martin as an independent director effective January 1, 2027, expanding its board from 10 to 11 members. He will receive an annual cash retainer of $70,000 and an initial restricted stock unit grant valued at $93,333.

View
Proposed Sales
Value
$184.2K
Shares
400
Filed
Nov 10, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 20, 2026
View
Investor Relations
Latest news
Intuitive Appoints Aaron Martin t…
Published
Nov 2, 2026
View

Performance

5D 20D 120D MTD YTD
ISRG -5.0% +1.1% +4.6% +1.3% -22.7%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -3.3% +4.5% +6.0% +3.4% -31.2%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$17.40B
Spent (derived)
$15.60B
Remaining
$1.80B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1035267 CUSIP 46120E602 13F (30d) 1740 filings 1642 filers Visit website Investor relations